Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)24.90
  • Today's Change2.00 / 8.73%
  • Shares traded4.16m
  • 1 Year change+33.16%
  • Beta2.8377
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)461.61m
  • Net income in HKD-1.16bn
  • Incorporated2017
  • Employees520.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beijing Luzhu Biotechnology Co Ltd0.00-308.74m4.30bn148.00--4.16-----1.52-1.520.005.140.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Cutia Therapeutics219.31m-578.29m4.44bn360.00--3.39--20.25-1.90-1.900.72054.310.12062.316.93735,949.90-31.81---35.82--50.33---263.68--4.82--0.1818--1,110.83---253.30------
Shandong Boan Biotechnology Co Ltd793.90m68.17m4.90bn813.0068.443.0433.906.180.13370.13371.563.010.30691.102.60976,501.302.63--3.43--74.10--8.59--1.034.010.3224--19.80--64.02------
Sihuan Pharmaceutical Holdings Group Ltd1.94bn-41.69m5.03bn2.65k--1.03--2.60-0.0045-0.00450.20850.52320.15060.96411.98673,759.10-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.52-1.390.181---14.70-8.6097.23--0.9325--
AIM Vaccine Co Ltd1.31bn-1.31bn5.16bn1.56k--1.34--3.95-1.08-1.081.083.190.14620.63251.10804,189.20-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Consun Pharmaceutical Group Ltd3.02bn922.45m5.23bn3.18k5.411.285.181.731.141.143.754.830.52092.0011.77966,028.2015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
Shanghai Fudan-Zhangjiang Bio-Pharm. Co811.75m122.05m5.68bn948.0015.450.7139--6.990.11580.11580.76322.510.25041.261.35856,278.103.757.034.669.0591.2592.1714.9717.263.78--0.005239.16-17.502.78-21.28-0.632620.49--
Tong Ren Tang Technologies Co Ltd7.58bn717.74m6.30bn4.01k8.780.80524.390.83080.56040.56045.926.110.50260.98815.221,849,466.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.35bn779.0012.861.6710.284.620.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
China Shineway Pharmaceutical Group Ltd4.64bn1.22bn6.62bn3.44k4.960.81774.741.431.611.616.149.780.44761.285.261,349,568.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.11bn1.82bn7.29bn4.89k4.010.76333.461.192.072.076.9410.860.42722.503.571,323,156.0011.698.0317.2711.8178.9079.9727.3720.801.9325.510.212615.8168.0820.182,501.2416.15-11.50--
Cansino Biologics Inc672.22m-955.84m7.96bn1.49k--0.9408--11.84-3.87-3.872.7222.590.06761.280.8385449,948.20-10.15-4.27-13.73-5.6014.38---150.19-27.722.19--0.3028---66.52213.94-63.04--30.60--
Everest Medicines Ltd461.61m-1.16bn8.10bn520.00--1.64--17.54-3.61-3.611.4315.160.07565.233.221,068,552.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
SSY Group Ltd6.47bn1.37bn11.30bn5.80k8.301.566.181.750.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Luye Pharma Group Ltd6.96bn849.73m11.36bn5.27k13.370.79126.641.630.22590.22591.853.820.2362.442.841,321,269.003.112.805.474.4568.7370.5313.1810.391.202.960.401611.822.703.50-11.94-16.39-14.05--
Data as of Sep 20 2024. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.57%Per cent of shares held by top holders
HolderShares% Held
Janchor Partners Ltd.as of 30 Sep 202315.88m4.88%
The Vanguard Group, Inc.as of 04 Sep 20243.85m1.18%
BlackRock Advisors LLCas of 30 Jun 20243.11m0.96%
Bosera Asset Management Co., Ltd.as of 31 Dec 20233.05m0.94%
GF Fund Management Co., Ltd.as of 31 Dec 20232.32m0.71%
BlackRock Fund Advisorsas of 05 Sep 20242.18m0.67%
Dimensional Fund Advisors LPas of 05 Sep 20241.75m0.54%
Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 20231.12m0.34%
Wellington Management Co. LLPas of 27 Feb 2023678.30k0.21%
SSgA Funds Management, Inc.as of 05 Sep 2024452.00k0.14%
More ▼
Data from 13 Nov 2023 - 19 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.